APTIVATE: This study is evaluating how safe, tolerable and effective targeted therapy (called tuspetinib) is in people with relapsed or refractory acute myeloid leukaemiaA Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Summary

This study will run in three stages: dose escalation, dose exploration and dose expansion. In Part A (dose escalation), participants will receive tuspetinib daily. Dose escalation cohort is planned for up to 6 cohort levels. In Part B (dose exploration), participants will receive tuspetinib daily. Dose exploration is planned for up to 4 dose levels. Part C (dose expansion) consists of two treatment arms and participants and participants will be randomly assigned to either arm. Participants in Arm 1 will receive tuspetinib alone, daily. Participants in Arm 2 will receive tuspetinib plus venetoclax (another targeted therapy).

Treatment Type

Radiotherapy